ArticleCurrent oncology (Toronto, Ont.)2020

A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer.

A Parmar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.